Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Open Access
- 1 June 2010
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (6), 2664-2671
- https://doi.org/10.1210/jc.2009-2461
Abstract
Purpose: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinases that also inhibits rearranged during transfection kinase activity. Vandetanib (300 mg/d) has previously demonstrated antitumor activity in patients with advanced hereditary medullary thyroid cancer (MTC). This study investigated the efficacy and safety of 100 mg/d vandetanib in patients with advanced hereditary MTC. Patients and Methods: Eligible patients with unresectable, measurable, locally advanced, or metastatic hereditary MTC received 100 mg/d vandetanib. Upon disease progression, eligible patients could enter postprogression treatment with 300 mg/d vandetanib until a withdrawal criterion was met. The primary objective was to assess the objective response rate by response evaluation criteria in solid tumors. Results: The study comprised 19 patients (13 males, six females; mean age 45 yr). Confirmed objective partial responses were observed in three patients, yielding an objective response rate of 16% (95% confidence interval 3.4–39.6). Stable disease lasting 24 wk or longer was reported in a further 10 patients (53%); the disease control rate was therefore 68% (95% confidence interval 43.4–87.4). Serum levels of calcitonin and carcinoembryonic antigen showed a sustained 50% or greater decrease from baseline in 16% (three of 19) and 5% (one of 19) of patients, respectively. Adverse events were predominantly grade 1 or 2 and consistent with previous vandetanib monotherapy studies. Conclusions: Vandetanib at a once-daily dose of 100 mg has clinically relevant antitumor activity in patients with locally advanced or metastatic hereditary MTC and an overall acceptable safety profile.Keywords
This publication has 30 references indexed in Scilit:
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerJournal of Clinical Oncology, 2010
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2009
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling timesActa Endocrinologica, 2008
- New therapeutic approaches to treat medullary thyroid carcinomaNature Clinical Practice Endocrinology & Metabolism, 2008
- Medullary thyroid cancer: therapeutic targets and molecular markersCurrent Opinion in Oncology, 2007
- Prognosis of medullary thyroid carcinomaCancer, 2006
- Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumorsAnnals Of Oncology, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- RETProto-Oncogene Mutations in Multiple Endocrine Neoplasia Type 2 and Medullary Thyroid CarcinomaHormone Research, 1997